Chao Han1, Xuan Ding1, Mengmeng Li2, Ningning Luo2, Yingxue Qi2, Chengwei Wang3. 1. Department of Neurosurgery, Cheeloo College of Medicine, The Second Hospital, Shandong University, Jinan, China. 2. The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd; Nanjing Simcere Medical Laboratory Science Co., Ltd; The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,, Nanjing, China. 3. Department of Neurosurgery, Cheeloo College of Medicine, The Second Hospital, Shandong University, Jinan, China. wangchengwei@sdu.edu.cn.
Abstract
BACKGROUND: Epidermal growth factor receptor (EGFR) is a crucial driven gene in non-small cell lung cancer (NSCLC), and the EGFR mutation rate in lung squamous cell carcinoma (SCC) is only 3 ~ 6.92%. Uncommon EGFR mutations, such as S768I, L861Q and G719X, accounting for approximately 15% of NSCLC harboring EGFR mutation. Afatinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI), has been approved for NSCLC harboring uncommon mutations by the FDA in 2018. In our report, the lung SCC patient harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib. CASE PRESENTATION: A case of a lung SCC patient harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib, and new MYC amplification was detected by next-generation sequencing (NGS) after disease progression. CONCLUSIONS: This case first identified a patient with lung squamous cell carcinoma harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib and achieved 11 months of progression-free survival (PFS). Then, new MYC amplification was detected after disease progression, indicating that MYC amplification may be one of the reasons for afatinib resistance.
BACKGROUND: Epidermal growth factor receptor (EGFR) is a crucial driven gene in non-small cell lung cancer (NSCLC), and the EGFR mutation rate in lung squamous cell carcinoma (SCC) is only 3 ~ 6.92%. Uncommon EGFR mutations, such as S768I, L861Q and G719X, accounting for approximately 15% of NSCLC harboring EGFR mutation. Afatinib, a second-generation EGFR-tyrosine kinase inhibitor (TKI), has been approved for NSCLC harboring uncommon mutations by the FDA in 2018. In our report, the lung SCC patient harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib. CASE PRESENTATION: A case of a lung SCC patient harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib, and new MYC amplification was detected by next-generation sequencing (NGS) after disease progression. CONCLUSIONS: This case first identified a patient with lung squamous cell carcinoma harboring uncommon compound EGFR mutation (G719A and R776C) benefited from afatinib and achieved 11 months of progression-free survival (PFS). Then, new MYC amplification was detected after disease progression, indicating that MYC amplification may be one of the reasons for afatinib resistance.
Authors: Hayley J Sharpe; Gregoire Pau; Gerrit J Dijkgraaf; Nicole Basset-Seguin; Zora Modrusan; Thomas Januario; Vickie Tsui; Alison B Durham; Andrzej A Dlugosz; Peter M Haverty; Richard Bourgon; Jean Y Tang; Kavita Y Sarin; Luc Dirix; David C Fisher; Charles M Rudin; Howard Sofen; Michael R Migden; Robert L Yauch; Frederic J de Sauvage Journal: Cancer Cell Date: 2015-03-09 Impact factor: 31.743
Authors: Teresa Moran; Alvaro Taus; Edurne Arriola; Carlos Aguado; Manuel Dómine; Ana Gómez Rueda; Antonio Calles; Susana Cedrés; Nuria Viñolas; Dolores Isla; Ramón Palmero; María Sereno; Victor Diaz; Oscar Juan; Raquel Marsé; Paloma Martín Martorell; José Miguel Sánchez Torres Journal: Clin Lung Cancer Date: 2020-04-25 Impact factor: 4.785